

Simon J Hogg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3913938/publications.pdf>

Version: 2024-02-01

26
papers

1,761
citations

516710

16
h-index

580821

25
g-index

28
all docs

28
docs citations

28
times ranked

2940
citing authors

#	ARTICLE	IF	CITATIONS
1	BET Inhibition Enhances TNF-Mediated Antitumor Immunity. <i>Cancer Immunology Research</i> , 2022, 10, 87-107.	3.4	8
2	Mechanisms of Resistance to Noncovalent Brutonâ€™s Tyrosine Kinase Inhibitors. <i>New England Journal of Medicine</i> , 2022, 386, 735-743.	27.0	87
3	Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML. <i>Cancer Discovery</i> , 2022, 12, 1560-1579.	9.4	13
4	Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma. <i>Leukemia</i> , 2022, 36, 1654-1665.	7.2	9
5	Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia. <i>EMBO Molecular Medicine</i> , 2022, 14, e15203.	6.9	10
6	Serine Biosynthesis Is a Metabolic Vulnerability in FLT3-ITDâ€™Driven Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2021, 11, 1582-1599.	9.4	35
7	Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition. <i>Nature Genetics</i> , 2021, 53, 707-718.	21.4	61
8	Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition. <i>Molecular Cell</i> , 2021, 81, 2183-2200.e13.	9.7	59
9	The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer. <i>Cell</i> , 2021, 184, 3143-3162.e32.	28.9	103
10	Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. <i>Cell</i> , 2021, 184, 4032-4047.e31.	28.9	131
11	Whole genome CRISPR screening identifies TOP2B as a potential target for IMiD sensitization in multiple myeloma. <i>Haematologica</i> , 2021, 106, 2013-2017.	3.5	7
12	Impaired RAS Proteolysis Drives Clonal Hematopoietic Transformation. <i>Blood</i> , 2021, 138, 356-356.	1.4	0
13	Temporal Analysis of Brd4 Displacement in the Control of B Cell Survival, Proliferation, and Differentiation. <i>Cell Reports</i> , 2020, 33, 108290.	6.4	4
14	The natural function of the malaria parasiteâ€™s chloroquine resistance transporter. <i>Nature Communications</i> , 2020, 11, 3922.	12.8	53
15	Targeting the epigenetic regulation of antitumour immunity. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 776-800.	46.4	264
16	CDK13 cooperates with CDK12 to control global RNA polymerase II processivity. <i>Science Advances</i> , 2020, 6, .	10.3	79
17	Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. <i>Cancer Cell</i> , 2020, 38, 198-211.e8.	16.8	99
18	<i>ZRSR2</i> Mutation Induced Minor Intron Retention Drives MDS and Diverse Cancer Predisposition Via Aberrant Splicing of <i>LZTR1</i>. <i>Blood</i> , 2020, 136, 10-11.	1.4	1

#	ARTICLE	IF	CITATIONS
19	Tumor immune evasion arises through loss of TNF sensitivity. <i>Science Immunology</i> , 2018, 3, .	11.9	244
20	BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1. <i>Cell Reports</i> , 2017, 18, 2162-2174.	6.4	244
21	The SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock. <i>Oncogenesis</i> , 2016, 5, e216-e216.	4.9	24
22	Development of single and mixed isoform selectivity PI3K \hat{I} inhibitors by targeting Asn836 of PI3K \hat{I} . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 4790-4794.	2.2	11
23	BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2030-2041.	4.1	57
24	CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo. <i>Leukemia</i> , 2015, 29, 1437-1441.	7.2	120
25	Letter to the Editor, "BET Inhibitor JQ1 Blocks Inflammation and Bone Destruction", <i>Journal of Dental Research</i> , 2015, 94, 229-229.	5.2	2
26	The Drug Vehicle and Solvent N-Methylpyrrolidone Is an Immunomodulator and Antimyeloma Compound. <i>Cell Reports</i> , 2014, 7, 1009-1019.	6.4	34